HIV Therapies Add 20 Years and Cut Infections
Just a few decades ago, the HIV/AIDS epidemic gripped the U.S. with devastating force. HIV cases soared, with limited understanding of the virus and a scarcity of effective treatments. At its peak, HIV was the leading cause of death among men aged 25–44.1
Fast forward to today, and the landscape is dramatically different. Thanks to expanded prevention strategies and groundbreaking treatments like antiretroviral therapies (ARTs) and pre-exposure prophylaxis (PrEP), death rates have plummeted, adherence to treatment has improved and life expectancy for those living with HIV has increased significantly.2 3 These advancements have not only saved lives but have also given hope for a future without HIV/AIDS.
Biopharmaceutical researchers are pushing boundaries, developing next-generation therapies like long-acting ARTs and PrEP, which could reduce treatment schedules to as little as once every three to six months.4 Beyond convenience, these innovations represent a giant leap toward a singular goal: curing HIV completely.
1 American Psychological Association. AIDS in the 90s: Did You Know?. 2017.
2 IJID Regions. Exploring the impact of therapeutic advances in HIV-related mortality in the United States. March 2024.
3 The Lancet HIV. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. May 2023.
4 Expert Opin Drug Deliv. Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research. July 2020.
Our Work in Action
With the support of a unique ecosystem and policy environment that foster transformative advancements, this progress positions America as the global leader in biopharmaceutical innovation.
